2 hours Ago By ABMN Staff
NovoCure Limited ( NASDAQ:NVCR – Get Free Report ) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $32.
67. Several research analysts have recently commented on NVCR shares. HC Wainwright reiterated a “buy” rating and set a $38.
00 price target on shares of NovoCure in a report on Tuesday, January 14th. Piper Sandler boosted their target price on shares of NovoCure from $28.00 to $42.
00 and gave the company an “overweight” rating in a report on Friday, December 13th. Evercore ISI raised shares of NovoCure from an “in-line” rating to an “outperform” rating and increased their price target for the company from $18.00 to $30.
00 in a research note on Monday, December 2nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of NovoCure in a research report on Monday, January 13th.
View Our Latest Report on NVCR NovoCure Stock Down 3.9 % NovoCure ( NASDAQ:NVCR – Get Free Report ) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported ($0.
28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.
The business had revenue of $155.10 million during the quarter, compared to analyst estimates of $143.95 million.
NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%.
The business’s revenue was up 21.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.
46) earnings per share. As a group, sell-side analysts predict that NovoCure will post -1.3 EPS for the current fiscal year.
Institutional Trading of NovoCure Institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund raised its stake in shares of NovoCure by 201.9% in the fourth quarter.
New York State Common Retirement Fund now owns 99,595 shares of the medical equipment provider’s stock valued at $2,968,000 after acquiring an additional 66,602 shares in the last quarter. Truist Financial Corp acquired a new stake in NovoCure in the 4th quarter valued at about $340,000. Principal Financial Group Inc.
purchased a new position in shares of NovoCure in the 4th quarter valued at about $272,000. Rhumbline Advisers grew its position in shares of NovoCure by 2.2% during the fourth quarter.
Rhumbline Advisers now owns 145,469 shares of the medical equipment provider’s stock worth $4,335,000 after buying an additional 3,115 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in shares of NovoCure by 70.
7% during the fourth quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 781 shares during the period.
84.61% of the stock is currently owned by hedge funds and other institutional investors. NovoCure Company Profile ( Get Free Report NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
The company’s TTFields devices include Optune Gio and Optune Lua. Featured Stories Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter .
.
